Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS

Clinical trial NCT06925555 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06925555
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

EBV-Positive Diffuse Large B-Cell Lymphoma, Nos Brentuximab Vedotin

Start date: 2025-09-01
Primary completion: 2028-12-30
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.